Camurus AB (OSTO:CAMX)

kr 589 0 (0%) Market Cap: 34.68 Bil Enterprise Value: 31.95 Bil PE Ratio: 132.17 PB Ratio: 11.14 GF Score: 65/100

Q3 2024 Camurus AB Earnings Call Transcript
Nov 07, 2024

kr631 (+5.34%)

Earnings
Q2 2024 Camurus AB Earnings Call Transcript
Jul 16, 2024

kr676.5 (+4.08%)

Earnings
Q1 2024 Camurus AB Earnings Call Transcript
May 08, 2024

kr535 (+7.82%)

Earnings
Q4 2023 Camurus AB Earnings Call Transcript
Feb 15, 2024

kr446.8 (-17.79%)

Earnings
Q3 2023 Camurus AB Earnings Call Transcript
Nov 09, 2023

kr399.8 (+13.84%)

Earnings
Half Year 2023 Camurus AB Earnings Call Transcript
Jul 18, 2023

kr302.8 (+7.83%)

Earnings
Camurus AB Special Call Transcript
Jun 20, 2023
Q1 2023 Camurus AB Earnings Call Transcript
May 10, 2023

kr253 (+1.52%)

Earnings
Q4 2022 Camurus AB Earnings Call Transcript
Feb 14, 2023

kr240.8 (-2.35%)

Earnings
Q3 2022 Camurus AB Earnings Call Transcript
Nov 10, 2022

kr263.4 (+7.86%)

Earnings
Camurus AB Corporate Analyst Meeting Transcript
Sep 06, 2022
Q2 2022 Camurus AB Earnings Call Transcript
Jul 15, 2022

kr224.6 (+2.37%)

Earnings
Q1 2022 Camurus AB Earnings Call Transcript
May 12, 2022

kr170 (+2.22%)

Earnings
Q4 2021 Camurus AB Earnings Call Transcript
Feb 16, 2022

kr141.4 (+1.87%)

Earnings
Q3 2021 Camurus AB Earnings Call Transcript
Nov 04, 2021

kr149.2 (-6.75%)

Earnings
Q2 2021 Camurus AB Earnings Call Transcript
Jul 15, 2021

kr195 (-12.95%)

Earnings
Q1 2021 Camurus AB Earnings Call Transcript
May 06, 2021

kr210 (-1.41%)

Earnings
Full Year 2020 Camurus AB Earnings Call Transcript
Feb 11, 2021

kr209 (+1.46%)

Earnings
Nine Months 2020 Camurus AB Earnings Call Transcript
Nov 05, 2020

kr206.5 (+3.98%)

Earnings
Q2 2020 Camurus AB Earnings Call Transcript
Jul 16, 2020

kr170 (+10.10%)

Earnings
Camurus AB at Solebury Trout European Biotech Investor Day Transcript
Jun 25, 2020
Q1 2020 Camurus AB Earnings Call Transcript
May 07, 2020

kr127.4 (-0.93%)

Earnings
Q3 2019 Camurus AB Earnings Call Transcript
Nov 08, 2019

kr90 (-1.32%)

Earnings

Camurus AB Special Call Transcript

Jun 20, 2023 / 11:30AM GMT

Release Date Price: kr286 (+3.85%)

Transcript

Operator

Welcome to today's press conference with Camurus. (Operator Instructions) Now I'll hand the conference over to CEO and President, Fred Tiberg. Please go ahead.

Fredrik Tiberg;publ;President

Camurus AB;CEO, CSO & Director

()- -

Thank you so much, (inaudible), and hi, everyone, and welcome to today's conference call, where we will present the top line results from our pivotal acromegaly Phase III trial ACROINNOVA, and we're very pleased to do that today.

We -- before going into the presentation, please note our forward-looking statements. As usual, we will start this presentation with a short summary of the results, then our Chief Medical Officer; Alberto Pedroncelli will give a brief introduction to acromegaly octreotide SC depot and also to himself. Yes, then we will have a more detailed presentation of the top line results, followed by next steps and Q&A.

So with me in the call, I have Alberto, of course, here; and then also our VP Clinical Development and Pharmacovigilance, Agneta Svedberg.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.